The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with...
Incidence-based mortality is also projected to increase with disproportionately higher rates for Black women compared with white women. Incidence and mortality rates for most cancer types have been on the decline in the United...
Participating in a structured exercise program after treatment was associated with a reduced risk of recurrence in people who had colon cancer.
A single-cell atlas helped clarify diverse forms of acute myeloid leukemia, with potential implications for improving diagnostic, prognostic, and therapeutic capabilities.
Low-dose aspirin reduces cancer risk for people with Lynch syndrome, and breast cancer survivors may have lower risk for Alzheimer’s than the general public.
For June 2025, the editors of AACR's journals highlighted studies on pancreatic cancer interception, breast cancer risk prediction, and more.
Cancer Today's 2025 summer issue covers the expanded use of neoadjuvant immunotherapy, PSMA-targeted therapy for prostate cancer, and more.
A study suggests that modifying a patient’s gut microbiome could make their cancer more likely to respond to CAR T-cell therapy.
The FDA has approved datopotamab deruxtecan-dlnk for certain patients with non-small cell lung cancer. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to datopotamab deruxtecan-dlnk (Datroway) for the treatment of adult...
Surgery to remove fallopian tubes can lower ovarian cancer risk, and NIH staff cuts lead to delays for patients with no other treatment options.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More